Paul joined EyeBio as Senior Vice President of Chemistry, Manufacturing, and Controls (CMC). He is responsible for early candidate selection and development of EyeBio’s large-molecule portfolio.
Paul has more than 35 years of experience in the biotechnology industry. With over 50 peer-reviewed publications, he is an expert in antibody drug development and expression. Previously, Paul was Senior Director and Head of Antibody Biology at UCB, where he was responsible for the company’s early antibody pipeline and oversaw the transition of UCB’s novel biological entities (NBEs) from the research stage into development. While at UCB, Paul was actively involved in the development of both Evenity® (romosozumab) and Bimzelx® (bimekizumab).
Paul received B.Sc. in Biochemistry from Southampton University, and he completed his Ph.D. at Sheffield University.